BioShares Biotechnology Clinical Trials ETF (BBC) ETF
Expense Ratio: 0.79% | AUM: 43.80M | Issuer: BioShares
BBC Daily Price Range
BBC 52-Week Price Range
BBC - Real-Time SMART Grade™
A
Strong Buy
Overall SMART Grade
BBC has a real-time SMART Grade of A (Strong Buy).
Learn More About SMART Grades™BBC - Profile & Info
The investment objective of the Virtus LifeSci Biotech Clinical Trials ETF seeks investment results that correspond to the price and yield performance of the BioShares Biotechnology Clinical Trials Index. The clinical trials index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development.
| Issuer | BioShares |
| Expense Ratio | 0.79% |
| Assets Under Management (AUM) | 43.80M |
| Underlying Index | BioShares Biotechnology Clinical Trials Index |
| Asset Class | Portfolio-Multi Asset |
| ETF Category | Health & Biotech ETFs |
| Net Asset Value (NAV) | $43.80 |
| Options? | Yes |
| Total Holdings | 166 |
BBC - Top Holdings
BBC - Top Stories
View All BBC News
BBC - Price/Volume Stats
| Current price | $54.08 |
| Prev. close | $52.12 |
| Day low | $52.38 |
| Day high | $54.29 |
| 52-week high | $54.37 |
| 52-week low | $23.00 |
| Day Volume | 8,200 |
| Avg. volume | 8,078 |
| Dividend yield | 0.00% |
BBC - Recent Returns
| 1-mo | 5.43% |
| 3-mo | 26.01% |
| 6-mo | 24.49% |
| 1-year | 41.34% |
| 3-year | 81.17% |
| 5-year | 160.22% |
| YTD | 9.05% |
| 2020 | 30.32% |
| 2019 | 63.81% |
| 2018 | -18.29% |
| 2017 | 56.12% |
| 2016 | -36.63% |
BBC - Stock Chart
BBC - Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Free Investing Ideas Newsletter!
Most Popular Articles
A Deep Look At The Vanguard Total Stock Market ETF (VTI)
Time For Inverse Bond ETFs? (TBF, TLT, TBT, TMV, TTT)
A Deeper Look At The Vanguard Total International Stock ETF (VXUS)
Our Exclusive Tools
